What are the latest figures on the peptide and anticoagulant drugs market’s size and projected CAGR?
The peptide and anticoagulant drugs market size has grown at grown rapidly in recent years. It will grow from $1.41 billion in 2024 to $1.56 billion in 2025 at a compound annual growth rate (CAGR) of 10.6%. The growth in the historic period can be attributed to increased healthcare expenditure, increased healthcare investments, rising market liberalization, a rise in the number of infected patients globally, and an increase in the incidence of genetic conditions.
The peptide and anticoagulant drugs market size is expected to see rapid growth in the next few years. It will grow to $2.30 billion in 2029 at a compound annual growth rate (CAGR) of 10.3%. The growth in the forecast period can be attributed to the rising prevalence of chronic diseases, aging population, rising prevalence of cancer, emerging markets expansion, and increasing burden of cardiovascular diseases. Major trends in the forecast period include advancements in biotechnology, technological developments in drug delivery, improved diagnostic techniques, advancements in pharmacology, and the development of anticoagulant products.
Get Your Free Sample of The Global Peptide And Anticoagulant Drugs Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21252&type=smp
Which Market drivers have played a significant role in driving the peptide and anticoagulant drugs market?
The rising prevalence of chronic diseases is expected to propel the growth of the peptide and anticoagulant drugs market going forward. Chronic diseases refer to long-term health conditions that persist over an extended period of time, often for years or even a lifetime. The rising prevalence of chronic diseases is driven by factors such as aging populations, unhealthy lifestyles, and increased incidence of risk factors such as obesity, hypertension, and diabetes. Peptide and anticoagulant drugs are used in chronic diseases to manage conditions such as cardiovascular diseases, thrombosis, and stroke by preventing blood clots and targeting specific disease pathways for improved patient outcomes. For instance, in May 2023, according to reports published by the Centers for Disease Control and Prevention, a US-based government organization, heart disease and cancer deaths totaled 695,547 in 2022, which is an increase from the previous year compared with 605,213 in 2021. Therefore, the rising prevalence of chronic diseases is driving the growth of the peptide and anticoagulant drugs market.
What are the key segments within the peptide and anticoagulant drugs market?
The peptide and anticoagulant drugs market covered in this report is segmented –
1) By Type: Hormonal, Antibiotic, Ace Inhibitor, Antifungal, Other Types
2) By Route Of Administration: Oral, Injectable, Other Routes Of Administration
3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels
4) By Application: Infectious Diseases, Gynecology, Cancer, Diabetes, Cardiology, Osteoporosis, Other Applications
5) By End-users: Hospitals, Specialty Clinics, Homecare, Other End-users
Subsegments:
1) By Hormonal: Peptide Hormones, Steroid Hormones, Thyroid Hormones, Other Hormones
2) By Antibiotic: Beta-Lactams, Macrolides, Tetracyclines, Fluoroquinolones, Other Antibiotics
3) By ACE Inhibitor: Captopril, Enalapril, Lisinopril, Ramipril, Other ACE Inhibitors
4) By Antifungal: Azoles, Echinocandins, Polyenes, Allylamines, Other Antifungals
5) By Other Types: Immunosuppressants, Antineoplastic Agents, Cardiovascular Drugs, Other Peptide And Anticoagulant Drugs
Order your report now for swift delivery
Which key players are shaping the peptide and anticoagulant drugs market?
Major companies operating in the peptide and anticoagulant drugs market are Pfizer Inc., Merck & Co. Inc., Bayer AG, F. Hoffmann-La Roche Ltd, Sanofi S.A., Abbott Laboratories, Novartis AG, Novo Nordisk A/S, Viatris Inc., Baxter International Inc., Boehringer Ingelheim International GmbH, Sun Pharmaceutical Industries Limited, Bachem Holding AG, Bharat Serums and Vaccines Limited, Wockhardt Limited, AmbioPharm Inc., MITS Healthcare Private Limited, Siddha Pharmacy, Circle Pharma Inc., Tenwel Pharmaceuticals Pvt. Ltd.
Which transformative trends will shape the peptide and anticoagulant drugs market landscape?
Major companies operating in the peptide and anticoagulant drugs market are focusing on advancements in anticoagulant therapies, such as oral anticoagulants, to enhance efficacy, improve patient compliance, and reduce the risk of bleeding complications. An oral anticoagulant is a medication taken by mouth to prevent blood clots by inhibiting clotting factors in the blood. For instance, in April 2024, Cadrenal Therapeutics Inc., a US-based pharmaceutical company, received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for tecarfarin, its late-stage oral anticoagulant. Tecarfarin is designed to be a novel, reversible blood thinner aimed at reducing the risk of heart attacks, strokes, and mortality associated with blood clots in patients with rare cardiovascular conditions. The ODD applies specifically to the prevention of thromboembolism and thrombosis in patients with implanted mechanical circulatory support devices, including left ventricular assist devices (LVADs), right ventricular assist devices (RVADs), ventricular assist devices (VADs), biventricular assist devices, and total artificial hearts.
How do regional factors impact the peptide and anticoagulant drugs market, and which region is the largest contributor?
North America was the largest region in the peptide and anticoagulant drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peptide and anticoagulant drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Peptide And Anticoagulant Drugs Market Report 2025 Offer?
The peptide and anticoagulant drugs market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Peptide and anticoagulant drugs are therapeutic agents where peptide drugs are short chains of amino acids that mimic natural biological molecules, and anticoagulant drugs prevent blood clotting by inhibiting clotting factors. Some anticoagulants, like hirudin and bivalirudin, are peptide-based, directly inhibiting thrombin to prevent thrombosis. These drugs are crucial in treating conditions such as deep vein thrombosis, pulmonary embolism, and stroke.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21252
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
